

# PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2019) - **PreveCeutical Medical Inc.** (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (**the "Company" or "PreveCeutical"**), announces the Company's research team at the University of Queensland has filed an application to a local hospital's Human Ethics Committee (the "**Human Ethics Committee**") to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel ("**Sol-gel**") drug delivery research and development program (the "**Sol-gel Program**").

PreveCeutical has previously demonstrated effective delivery and retention of the Sol-gels to the olfactory epithelium in an adult human nasal cast using a custom applicator device (the "**Sol-gel Applicator**") (see news release dated November 19, 2018).

PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar stated: "This is an important next step for the Sol-gel Program. Having demonstrated, in an *in-vitro* model, using an adult human nasal cast, that the Company's CBD Sol-gel is delivered to and retained directly at target tissue high in the nasal cavity when administered with the Sol-gel Applicator, we look forward to testing the Sol-gels on human nasal tissue. This will allow PreveCeutical to potentially deliver a host of therapeutics safely from nose-to-brain in a reliable and sustained manner, which remains a significant challenge for many companies, globally."

PreveCeutical believes that the outcomes of its Sol-gel Program may be of value to companies interested in delivering pharmaceuticals to the central nervous system (the "**CNS**"). Achieving patient benefit from the use of medicinal cannabis for the management of CNS conditions, such as epilepsy, anxiety and depression, may be a function of achieving effective and sustained delivery of the cannabis-based therapeutic to brain tissue. When taken orally, medicinal cannabis can cause gastrointestinal upset, and when absorbed across the gut it is broken down by enzymes. As common drug delivery methods do not provide effective and sustained delivery to the brain, the delivery of cannabinoids to the CNS is a universal problem.

Should the application to the Human Ethics Committee be granted, the final phase of the Sol-gel Program may begin. During the final phase, the Company intends to study and report on the delivery of the cannabis-infused Sol-gels to freshly explanted nasal mucosal tissue.

## **About PreveCeutical**

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit [www.PreveCeutical.com](http://www.PreveCeutical.com), follow us on Twitter: <http://twitter.com/PreveCeuticals> and Facebook: [www.facebook.com/PreveCeutical](http://www.facebook.com/PreveCeutical).

## **On Behalf of the Board of Directors**

*"Dr. Makarand (Mak) Jawadekar"*  
President & Chief Science Officer

## **For further information, please contact:**

Deanna Kress  
Director of Corporate Communications & Investor Relations  
+1-778-999-6063  
[deanna@PreveCeutical.com](mailto:deanna@PreveCeutical.com)

## **Forward-Looking Statements:**

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States *Private Securities Litigation Reform Act of 1995*. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the ability of the Company to have its application to acquire human nasal mucosal tissue by the Human Ethics Committee approved, and if approved, to acquire human nasal mucosal tissue, and the Company's anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts",

"intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the risks associated with the completion of Sol-gel Program, actual results from clinical trials, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise any therapeutics from the Company's research programs, pursue business partnerships, complete its research programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at [www.sedar.com](http://www.sedar.com).

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/44078>